Discuss how human genetic variations impact pharmacokinetics and pharmacodynamics of drugs and the application for use in the clinical setting.

Discuss how human genetic variations impact pharmacokinetics and pharmacodynamics of drugs and the application for use in the clinical setting.

Discuss how human genetic variations impact pharmacokinetics and pharmacodynamics of drugs and the application for use in the clinical setting. 150 150 Nyagu

Discuss how human genetic variations impact pharmacokinetics and pharmacodynamics of drugs and the application for use in the clinical setting.

Purpose
The purpose of this assignment is for students to discuss how human genetic variations impact pharmacokinetics and pharmacodynamics of drugs and the application for use in the clinical setting.

Activity Learning Outcomes
Through this discussion, the student will demonstrate the ability to:

Explain how pharmacogenomics is currently applied to clinical practice (CO 3,4,5).
Discuss the limitations of pharmacogenomics testing (CO 3,4,5).
Discuss ethical concerns related to pharmacogenomics testing and treatment (CO 3,4,5).

Due Date: Wed. 11:59pm MT of Week 1

The student must provide an initial response to the discussion topic by Wednesday, 11:59pm MT. Subsequent posts, including substantive responses to peer(s) and faculty questions must occur by Sunday, 11:59pm MT. A total of 3 substantive posts are required on 3 different days.

A 10% late penalty will be imposed for initial discussions posted after the deadline on Wednesday 11:59pm MT, regardless of the number of days late. NOTHING will be accepted after 11:59pm MT on Sunday (i.e. student will receive an automatic 0).

A 10% penalty will be imposed for not entering the minimum number of interactive dialogue posts (3) OR not posting on the minimum required number of days (3). NOTHING will be accepted after 11:59pm MT on Sunday (i.e. student will receive an automatic 0).

Total Points Possible: 100
Requirements:

In your initial post, respond to the following scenario (Hint: use the pharmgkb website to guide your responses):

Before initiating abacavir, an anti-retroviral, for a newly diagnosed HIV positive patient the nurse practitioner orders HLA-B*5701 allele genetic testing. The test confirms that the patient carries the HLA-B*5701 allele.
Describe what these results mean.
Should the nurse practitioner prescribe abacavir in this case? If not, state why.
A patient is prescribed antiplatelet therapy (clopidogrel) following an acute myocardial infarction (MI). Six months later, the patient suffers another acute MI. The patient has been adherent to therapy and the nurse practitioner suspects that clopidrogel may have been ineffective. How might genetic testing have been beneficial in this case?
Identify 2 limitations of pharmacogenomics testing. Explain.
Identify 2 ethical concerns of using pharmacogenomics testing. Explain.

* Textbooks, non-US journals, nursing journals not intended for advanced practice providers or websites intended for the general public are not considered scholarly.

DISCUSSION CONTENT

Category

Points

%

Description

Application of Course Knowledge

35

35%

Proper rationale and reasoning skills are demonstrated; AND
Information is taken from source(s) with appropriate interpretation/evaluation to develop a comprehensive analysis or synthesis of the topic at hand; AND
All of the posts make direct reference to concepts discussed in the lesson; AND
Posts are on topic and answer all presented questions which demonstrate a solid understanding of the topic.
(4 critical elements)

Support from Evidence-Based Practice (EBP)

35

35%

Discussion posts are supported with appropriate, scholarly sources; uses valid, relevant, and reliable outside sources to contribute to the threaded discussion; AND
Sources are published within the last 5 years (unless it is the most current CPG); AND
Reference lists are provided and in-text citations match; AND
Provides relevant evidence of scholarly inquiry clearly stating how the evidence informed or changed professional or academic decisions.
(4 critical elements)

Interactive Dialogue

15

15%

Student provides a substantive* response to at least one topic-related post of a peer; AND
Evidence from appropriate scholarly sources are included; AND
Reference lists are provided and in-text citations match; AND
Student responds to all direct faculty questions OR if student was not asked a direct question student responds to either a 2nd peer post or a faculty question directed towards another student.

(*) A substantive post adds new content or insights to the discussion thread and information from student’s original post is not reused in peer or faculty response.

(4 critical elements)

Total CONTENT Points= 85 pts

DISCUSSION FORMAT

Category

Points

%

Description

Grammar, Syntax, Spelling & Punctuation

15

15%

Discussion post has minimal grammar, syntax, spelling, punctuation, or APA format errors*

(*) APA style references and in text citations are required; however, there are no deductions for errors in indentation or spacing of references. All elements of the reference otherwise must be included.

Total FORMAT Points= 15 pts

DISCUSSION TOTAL= 100 pts

Textbooks and Resources
Required Textbooks
The following books are required for this course:

Woo, T. M., & Robinson, M. V. (2016). Pharmacotherapeutics for Advance Practice Nurse prescribers (4th ed.). F. A. Davis Company.

This textbook is available as an e-book and can be accessed from the module view.

American Psychological Association. (2020). Publication manual of the American Psychological Association (7th ed.). American Psychological Association. https://doi.org/10.1037/0000165-000

Week 1: Readings
Due Sunday by 11:59pm Points None
Woo, T. M. & Robinson, M. V. (2016). Pharmacotherapeutics for Advanced Practice Nurse Prescribers (4th ed.). F.A. Davis Company.

Chapter 2: Review of Basic Principles of Pharmacology (WO1.1)
Chapter 7: Cultural and Ethnic Influences in Pharmacotherapeutics (WO1.2)
Chapter 8: An Introduction to Pharmacogenomics (WO1.3)

APA